German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

NEW YORK/FRANKFURT — Merck KGaA, the German health care and technology group, said on Monday it is in advanced talks to acquire US cancer and rare diseases drugmaker SpringWorks Therapeutics.

Merck & Co. Inc. (MRK): Revenue from ... Jefferies singled out Structure Therapeutics Inc. (GPCR), Insmed Inc. (INSM) and SpringWorks Therapeutics Inc. (SWTX) Another biotech stock worth watching ...

Merck & Co. Inc. (MRK): Revenue from Merck ... Jefferies singled out Structure Therapeutics Inc. Insmed Inc. and SpringWorks Therapeutics Inc. Another biotech stock worth watching is Biohaven ...

BofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $84 from $87 and keeps a Buy rating on the shares. While Q1 ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a ...

So should SpringWorks Therapeutics (NASDAQ:SWTX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...